German (DAX) Pharma Industry Analysis

Industry Valuation and Performance

Has the German Pharma Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Thu, 21 May 2026	€95.0b	€67.4b	€511.4m	21.1x	185.8x	1.4x
Sat, 18 Apr 2026	€95.0b	€67.9b	-€883,908,858.50	19.3x	-107.5x	1.4x
Mon, 16 Mar 2026	€87.7b	€67.9b	-€900,283,686.17	18.5x	-97.4x	1.3x
Wed, 11 Feb 2026	€102.8b	€68.3b	€2.9b	17.9x	35.9x	1.5x
Fri, 09 Jan 2026	€97.3b	€68.3b	€2.9b	18.4x	33.9x	1.4x
Sun, 07 Dec 2025	€88.4b	€68.5b	€2.9b	17.7x	30.7x	1.3x
Tue, 04 Nov 2025	€77.7b	€68.8b	-€439,226,363.74	18.3x	-176.8x	1.1x
Thu, 02 Oct 2025	€84.5b	€68.8b	-€439,003,868.69	18.7x	-192.5x	1.2x
Sat, 30 Aug 2025	€77.7b	€68.9b	-€406,133,953.93	17.2x	-191.4x	1.1x
Mon, 28 Jul 2025	€80.1b	€69.4b	-€283,071,598.00	17.8x	-283.1x	1.2x
Wed, 25 Jun 2025	€77.0b	€69.4b	-€293,702,195.00	17.5x	-262.2x	1.1x
Fri, 23 May 2025	€76.1b	€69.4b	-€196,350,479.00	17.1x	-387.8x	1.1x
Sun, 20 Apr 2025	€73.9b	€69.3b	€463.1m	17.8x	159.6x	1.1x
Tue, 18 Mar 2025	€85.4b	€69.2b	€436.0m	21.3x	195.8x	1.2x
Thu, 13 Feb 2025	€81.8b	€69.2b	€2.0b	21.7x	40.3x	1.2x
Sat, 11 Jan 2025	€84.4b	€69.2b	€2.0b	23x	42x	1.2x
Mon, 09 Dec 2024	€83.1b	€69.2b	€2.0b	22.5x	41x	1.2x
Wed, 06 Nov 2024	€92.7b	€69.4b	€1.6b	20x	59.4x	1.3x
Fri, 04 Oct 2024	€99.8b	€69.3b	€1.5b	21.7x	67.9x	1.4x
Sun, 01 Sep 2024	€106.2b	€69.3b	€1.5b	25.8x	72.1x	1.5x
Tue, 30 Jul 2024	€100.9b	€69.2b	-€303,627,757.00	29.8x	-332.3x	1.5x
Thu, 27 Jun 2024	€95.7b	€69.2b	-€327,989,929.00	29.5x	-291.7x	1.4x
Sat, 25 May 2024	€102.7b	€69.2b	-€310,351,180.00	21.5x	-330.8x	1.5x
Mon, 22 Apr 2024	€91.6b	€70.0b	-€34,208,180.00	20.2x	-2678.8x	1.3x
Wed, 20 Mar 2024	€96.1b	€70.0b	€6.5m	18.7x	14799.9x	1.4x
Fri, 16 Feb 2024	€97.8b	€70.6b	-€650,504,143.00	19.7x	-150.3x	1.4x
Sun, 14 Jan 2024	€99.5b	€70.6b	-€650,504,143.00	20.3x	-152.9x	1.4x
Tue, 12 Dec 2023	€95.1b	€70.6b	-€650,606,256.00	18.3x	-146.1x	1.3x
Thu, 09 Nov 2023	€107.6b	€72.1b	€4.7b	17x	23x	1.5x
Sat, 07 Oct 2023	€114.0b	€72.1b	€4.7b	18.7x	24.4x	1.6x
Mon, 04 Sep 2023	€125.5b	€72.1b	€4.7b	22.2x	27x	1.7x
Wed, 02 Aug 2023	€124.5b	€74.1b	€6.5b	17.3x	19.3x	1.7x
Fri, 30 Jun 2023	€117.8b	€74.2b	€6.4b	18.4x	18.3x	1.6x
Sun, 28 May 2023	€128.4b	€74.1b	€6.4b	22.1x	20.1x	1.7x

Current Industry PE

Investors are optimistic on the German Pharmaceuticals industry, and appear confident in long term growth rates.

The industry is trading at a PE ratio of 186x which is higher than its 3-year average PE of 126x.

The industry is trading close to its 3-year average PS ratio of 1.4x.

Past Earnings Growth

The earnings for companies in the Pharmaceuticals industry have declined 57% per year over the last three years,
Revenues have also declined 3.1% per year.
This means overall sales from these companies are declining and profits are subsequently falling as well.

Industry Trends

Which industries have driven the changes within the German Healthcare industry?


DE Market	2.03%
Healthcare	2.58%
Pharma	2.22%
Pharma	2.22%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
BAYN Bayer	€39.23	3.3% +€1.2b	65.4%	PS0.9x
MRK Merck KGaA	€122.75	1.3% +€695.6m	4.2%	PE21.1x
DMP Dermapharm Holding	€49.05	4.6% +€106.5m	39.9%	PE16.9x
93M1 MPH Health Care	€26.50	25.0% +€22.7m	5.2%	PB0.6x
B8FK Biofrontera	€2.36	0.9% +€121.5k	-10.6%	PS1.1x

Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After A Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack

Bayer announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) and granted Priority Review designation for its investigational oral Factor XIa (FXIa) inhibitor, asundexian, for the prevention of secondary stroke in patients following a non-cardioembolic ischemic stroke or transient ischemic attack (TIA). The NDA is based on positive results from the global, pivotal Phase III OCEANIC-STROKE trial. The study results were presented at the International Stroke Conference 2026 in New Orleans and published in The New England Journal of Medicine. In 2023, asundexian was granted Fast Track Designation by the FDA as a potential treatment for stroke prevention in patients after a non-cardioembolic ischemic stroke. The FDA has now granted Priority Review for asundexian, a designation for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition. OCEANIC-STROKE met the primary efficacy outcome of time to first occurrence of ischemic stroke and the primary safety outcome of time to ISTH (International Society on Thrombosis and Haemostasis) major bleeding. Factor XIa (FXIa) is a protein in the blood coagulation pathway, also known as the blood clotting process, with different roles in hemostasis (normal clotting to stop bleeding) and thrombosis (harmful clot formation that can block blood vessels). FXIa has a minor role in the formation of a hemostatic plug (a clot that seals a blood vessel injury) that seals the leak at the site of vessel injury. However, FXIa is thought to contribute to the formation of pathological thrombus growth (abnormal clot growth) and vessel blockage.

German (DAX) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Price target decreased by 66% to €37.00

Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After A Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack

Dermapharm Holding SE, Annual General Meeting, Jun 26, 2026

First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

Cantourage Group SE, Annual General Meeting, Jun 24, 2026

Biofrontera AG, Annual General Meeting, Jun 10, 2026

Cannovum Cannabis AG, Annual General Meeting, Nov 20, 2025